As the page turned on 2025, optimism was high among life sciences dealmakers. Elections in the U.S. and other major economies had concluded, interest rates were poised to come in to focus, and the regulatory environment...more
8/27/2025
/ Acquisition Agreements ,
Biotechnology ,
Department of Health and Human Services (HHS) ,
Food and Drug Administration (FDA) ,
Foreign Investment ,
Global Dealmaking ,
Healthcare ,
Investment ,
Life Sciences ,
Merger Agreements ,
National Security ,
Pharmaceutical Industry ,
Prescription Drugs
Cautious Optimism for Deal Making. The general consensus is that we will likely see an increase in M&A and capital market transactions in the life sciences sector in 2025....more
1/22/2025
/ Acquisition Agreements ,
Artificial Intelligence ,
Biotechnology ,
Capital Markets ,
Data Protection ,
Healthcare ,
Investment ,
Life Sciences ,
Merger Agreements ,
Pharmaceutical Industry ,
Regulatory Agenda ,
Telehealth
Summary -
The 41st Annual JP Morgan Healthcare Conference in rainy San Francisco earlier this month was relatively low-key compared to pre-pandemic versions of the health care investment symposium, which returned this year...more